The global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs
Market was valued at approximately US$ 2.9 Bn in 2016 is projected to
register cumulative annual growth rate (CAGR) of over 3.2% from 2017
to 2025, according to a new report published by Transparency Market
Research titled “Methicillin-resistant Staphylococcus Aureus (MRSA)
Drugs Market – Global Industry Analysis, Size, Share, Growth,
Trends, and Forecast, 2017–2025”. The report suggests that rising
incidence of the development of antibiotic resistant strains among
all age groups are likely to spur the demand of MRSA Drugs in the
coming years (2017 to 2025). As key players introduce novel anti-MRSA
agents in developed markets such a North America and Europe, these
regions are likely to account for dominating share of the global MRSA
Drugs market. Established presence & wide distribution networks
of major players and growing market penetration of emerging players
are likely to boost growth of Asia Pacific MRSA Drugs market at a
CAGR of around 3.7% from 2017 to 2025.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1315
According to CDC, around 33% of the people carry staphylococcus
aureus, also known as staph, in their nose. But over the decades, few
strains of staph such as MRSA (Methicillin-resistant Staphylococcus
Aureus) have become resistant to some antibiotics that once destroyed
it. MRSA strains are thus a type of staph that are resistant to
beta-lactam antibiotic called methicillin. Around 1% of the
population carrying staphylococcus aureus on their nose or skin are
infected by MRSA. However, increased practice of prescribing
antibiotics, 50% of which are unnecessary and inappropriate, is
responsible to give rise to treatment-emergent resistance in
MRSA-infected patients. According to the CDC, resistance to
tigecycline and vancomycin, which are the effective and potent
therapeutic options for severe MRSA infection, has emerged. Such
treatment-emergent resistant strains developing in the MRSA-infected
patients are expected to restrain the growth of MRSA drugs market
during the forecast period.
The report offers detailed segmentation of global MRSA drugs market
on the basis of drug class, route of administration, and distribution
channel. Among the drug class, lipopeptide is poised to account for
leading share of the global market during the forecast period from
2017 to 2025. However, the segment is expected to lose its market
share from 31.6% in 2016 to 30.5% by the end of 2025, owing to the
loss of patent exclusivity for daptomycin in 2016, and emergence of
generic drug molecules in lipopeptide drug class. Key pharmaceuticals
companies such as Pfizer, Inc. involved in the manufacturing of
oxazolidinones against MRSA infection, and their strong positioning
in the global MRSA drugs market is likely to get boost the growth of
oxazolidinone segment during the forecast period.
Various route of administration offered in the report are oral and
parenteral. Parenteral route of administration accounted for highest
market share of 72.2% in 2016, due to the increased investment in the
pharmaceutical sector by key antibiotics manufacturers to boost the
production of intravenous anti-MRSA antibiotics. Oral route of
administration is expected to get a boost in terms of revenue by
2025, which is attributable to the key companies involved in the R&D
of anti-MRSA vaccines.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1315
Rise in number of players in the antibiotic manufacturing industry,
along with their widespread distribution channels are estimated to
propel the market share of the retail pharmacy segment by 2025.
Hospital pharmacy is expected to account for a market share of 51.0%
by 2025, owing to the increased number of multispecialty hospitals
across the globe, and their improved reimbursement policies. However,
online pharmacy is likely to register highest CAGR of 3.4% during
2017-2025, due to rise in e-commerce sales, and improvement in
digital sales channels to cater to the rising demand-supply gap for
antibiotics.
Geographically, the global MRSA drugs market is segmented into five
major regions, which are North America, Europe, Asia Pacific, Latin
America, and Middle East & Africa. In 2016, North America
accounted for the highest market share in terms of revenue, which is
attributable to the investments by U.S. based key players in the R&D
of screening tools for MRSA infection. Europe is the second most
prominent region in the global MRSA drugs market, which is projected
to grow during the forecast period, due to research grants by the
public & private players in the European countries to propel the
R&D of anti-MRSA antibiotics. However, huge patient pool in the
countries of China and India, and uncontrolled consumption of
antibiotics in India are estimated to fuel the growth of MRSA drugs
market in Asia Pacific with relatively significant CAGR of 3.7%
during 2017-2025.
The prominent players operating in the global MRSA Drugs Market are
Basilea Pharmaceutica Ltd., The Medicines Company, Theravance
Biopharma, Allergan, Merck & Co., Inc., and Pfizer, Inc.
Investing in the R&D and clinical trials of unique drug molecules
in topical dosage form is the major strategy being adopted by key
manufacturers to stay ahead in the rising competition.
Report Overview @
https://www.transparencymarketresearch.com/mrsa-drugs-market.html
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment